SynAct Pharma AB

Stockholm Stock Exchange SYNACT.ST

SynAct Pharma AB Return on Capital Employed (ROCE) for the year ending December 31, 2023: -110.04%

SynAct Pharma AB Return on Capital Employed (ROCE) is -110.04% for the year ending December 31, 2023, a -31.49% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

SynAct Pharma AB Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -83.69%, a 74.93% change year over year.
SynAct Pharma AB Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -333.80%.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

Stockholm Stock Exchange: SYNACT.ST

SynAct Pharma AB

CEO	Mr. Jeppe Ovli Ovlesen EE, MBA
IPO Date	July 11, 2016
Location	Sweden
Headquarters	Scheelevägen 2
Employees	5
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranous glomerulonephritis. It has a partnership with the University Of Örebro to study the reduction of inflammation in vascular disease. The company was founded in 2012 and is headquartered in Lund, Sweden.

Key trends

Past 5 years